Johnson & Johnson is poised to begin a roadshow to pitch shares of its consumer-healthcare business, the producer of household names such as Tylenol, in a test for an IPO market that has been in the doldrums for the past year, The Wall Street Journal’s Corrie Driebusch and Peter Loftus report. Kenvue plans to start meeting with prospective investors as early as Monday, people familiar with the matter said. The goal is to raise $3.5B or more in the offering at a valuation close to $40B, the people said. IPO roadshows typically last anywhere from a few days to a week ahead of the stock’s trading debut, the authors note. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ: